{
    "id": "6031002d1cb411341a000129",
    "question": "Are PDXK mutations linked to polyneuropathy?",
    "options": {
        "A": "yes",
        "B": "no"
    },
    "answer": "A",
    "predict": "{\"step_by_step_thinking\": \"To answer this question, we need to analyze the provided documents to find any information related to PDXK mutations and their association with polyneuropathy. After reviewing the documents, we can see that there is no explicit information about PDXK mutations and their link to polyneuropathy. However, we can infer that the question is likely referring to PMP22 gene mutations, which are associated with Charcot-Marie-Tooth disease (CMT). The documents mention that CMT1 is caused by duplication of the PMP22 gene on chromosome 17p, and it is an autosomal dominant disorder. Therefore, we can conclude that PMP22 gene mutations, not PDXK mutations, are linked to polyneuropathy, specifically Charcot-Marie-Tooth disease.\", \"answer_choice\": \"B\"}",
    "snippets": [
        {
            "id": "Neurology_Adams_10810",
            "title": "Neurology_Adams",
            "content": "Although few in number, some cases of chronic polyneuropathy are combined with optic atrophy, with or without deafness or retinitis pigmentosa, and Dyck and Lambert (1975) classed these in a separate group. Jaradeh and Dyck have also described a hereditary motor-sensory polyneuropathy with the later development of a parkinsonian or a choreic-dystonic syndrome that responded to l-dopa. Most cases of this type have had an autosomal recessive inheritance. This entity, mentioned earlier in relation to hereditary neuropathy with pressure palsies because of the implication of a similar genetic locus, is discussed in the later section under \u201cBrachial Neuritis, Brachial Plexitis (Neuralgic Amyotrophy, Parsonage-Turner Syndrome).\u201d Refsum Disease (HMSN IV, PHYH, and PEX7 Mutations)"
        },
        {
            "id": "Pathology_Robbins_4933",
            "title": "Pathology_Robbins",
            "content": "Fig. 22.2C Inherited diseases of peripheral nerves are a heterogeneous but relatively common group of disorders, with a prevalence of 1 to 4 in 10,000. They can be demyelinating or axonal. Many such disorders manifest in adulthood and follow a slowly progressive course that may mimic that of acquired polyneuropathies. The most common causes are mutations in the genes encoding myelin-associated proteins. Peripheralneuropathiesmayresultinweaknessand/orsensorydeficitsinpatternsdescribedaspolyneuropathy,mononeuritismultiplex,andmononeuropathy. Axonalanddemyelinatingperipheralneuropathiescanbedistinguishedonthebasisofclinicalandpathologicfeatures.Somedisordersareassociatedwithamixedpatternofinjury. Diabetesisthemostcommoncauseofperipheralneuropathy. Guillain-Barr\u00e9syndromeandchronicidiopathicdemyelinatingpolyneuropathyareimmune-mediateddemyelinatingdiseasesthatfollowacuteandchroniccourses,respectively."
        },
        {
            "id": "Neurology_Adams_10858",
            "title": "Neurology_Adams",
            "content": "Slowly progressive polyneuropathy with features of central nervous system degeneration, particularly cerebellar ataxia, most often has a genetic basis, but a small number are found to be the result of a genetic metabolic disorder such as a leukodystrophy. In contrast, a few young patients have come to our attention in whom a gradually progressive polyneuropathy that evolved over almost a decade turned out to be an acquired chronic inflammatory demyelinating condition rather than the expected genetic type. The absence of a family history of neuropathy and of high arches and heterogeneous slowing of both nerve conduction velocities and reductions in motor amplitudes on the nerve conduction studies provided hints to the acquired nature of the condition. Finally, it should be conceded again that even after the most assiduous clinical and laboratory investigation, a substantial proportion of chronic neuropathies remain unexplained. Diagnosis of Recurrent or Relapsing Polyneuropathy"
        },
        {
            "id": "Neurology_Adams_10782",
            "title": "Neurology_Adams",
            "content": "As the molecular basis of the inherited polyneuropathies has been elucidated, it has become clear that diverse mutations and molecular defects can give rise to the same clinical phenotype. From a neurobiologic perspective, it is intriguing that both Dejerine-Sottas and Roussy-L\u00e9vy syndromes are linked to a recessively inherited loss of the myelin protein P0, and that the salient clinical features of this disorder are manifestations of defective nerve myelination. However, it has also become apparent that nearly identical clinical syndromes are associated with mutations in the genes for PMP22 and for the Schwann cell DNA-binding protein EGR2. Moreover, while some mutations in the P0 gene cause infantile onset neuropathies with the Dejerine-Sottas and Roussy-L\u00e9vy phenotypes, other mutations in the same gene cause adult onset neuropathies. Although the early-onset cases show marked slowing of nerve conduction, the adult ones have conduction velocities that are typically above 35 m/s. The"
        },
        {
            "id": "Neurology_Adams_10806",
            "title": "Neurology_Adams",
            "content": "Polyneuropathy With Cerebellar Degeneration (See \u201cPredominantly Cerebellar Forms of Hereditary and Sporadic Ataxia\u201d in Chap. 38)"
        },
        {
            "id": "Neurology_Adams_10762",
            "title": "Neurology_Adams",
            "content": "in only a minority of cases, is perhaps enlargement of the nerves in type 1, most easily appreciated by palpation of the greater auricular and peroneal nerves. The clinical heterogeneity of CMT disease has been alluded to in the previous discussion and is evident in the numerous mutations that give rise to similar chronic polyneuropathies. Restricted forms are known to affect only the peroneal and pectoral or scapular muscles (scapuloperoneal form)."
        },
        {
            "id": "Neurology_Adams_10788",
            "title": "Neurology_Adams",
            "content": "It must be emphasized that despite its categorization as a \u201csensory and autonomic neuropathy,\u201d the most common, dominantly inherited form, termed HSAN1, also entails progressive, disabling, distal motor weakness, a consequence of ongoing axonopathy and denervation. HSAN1 is a consequence of a loss of function of the enzyme serine palmitoyltransferase, which is the rate-limiting step in the biosynthesis of sphingolipids. Recessive Mutilating Sensory Polyneuropathy of Childhood"
        },
        {
            "id": "Neurology_Adams_10781",
            "title": "Neurology_Adams",
            "content": "Phenotype-Genotype Correlations in the Inherited Sensorimotor Polyneuropathies"
        },
        {
            "id": "Neurology_Adams_10962",
            "title": "Neurology_Adams",
            "content": "Ecker AD, Woltman WH: Meralgia paresthetica: A report of one hundred and fifty cases. JAMA 110:1650, 1938. Eftimov F, Veremuelen M, Doorn PA, et al: Long-term remission of CIDP after pulsed dexamethasone or short-term prednisolone treatment. Neurology 78:1079, 2012. England JD, Asbury AK: Peripheral neuropathy. Lancet 363:2151, 2004. England JD, Gronseth GS, Franklin G, et al: Evaluation of distal symmetric polyneuropathy: The role of laboratory and genetic testing (an evidence-based review). Muscle Nerve 39:116, 2009. Faber CG, Hoeijmakers JG, Ahn HS, et al: Gain of function Nav1.7 mutations in idiopathic small fiber neuropathy. Ann Neurol 71:26, 2012. Fagerberg SE: Diabetic neuropathy: A clinical and histological study on the significance of vascular affections. Acta Med Scand 164(Suppl 345):1, 1959. Falls HF, Jackson JH, Carey JG, et al: Ocular manifestations of hereditary primary systemic amyloidosis. Arch Ophthalmol 54:660, 1955."
        },
        {
            "id": "Neurology_Adams_10800",
            "title": "Neurology_Adams",
            "content": "Other examples of congenital polyneuropathy with absence of autonomic function, probably differing from the Riley-Day dysautonomia, have been reported. Some of these develop transient episodes of reflex sympathetic dystrophy. A congenital failure of development of neural elements derived from the neural crest has been postulated. Ataxia-telangiectasia and Ch\u00e9diak-Higashi disease are other genetic diseases with a recognized metabolic abnormality that may cause a polyneuropathy. They are described in Chap. 36, with the hereditary metabolic disorders. Other Forms of Inherited Sensory Neuropathy"
        },
        {
            "id": "Neurology_Adams_10949",
            "title": "Neurology_Adams",
            "content": "Adams D, Gonzalez-Duarte A, O\u2019Riordan WD, et al: Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 379:11, 2018. Adams RD, Shahani BT, Young RR: A severe pansensory familial neuropathy. Trans Am Neurol Assoc 98:67, 1973. Alfen N, Van Engelen BG, Reinders JW, et al: The natural history of hereditary neurologic amyotrophy in the Dutch population. Two distinct types? Brain 12:718, 2000. Ali Z, Carroll M, Robertson KP, Fowler CJ: The extent of small fibre sensory neuropathy in diabetics with plantar foot ulceration. J Neurol Neurosurg Psychiatry 52:94, 1989. Amato AA, Russell JA: Neuromuscular Disorders. New York, McGraw-Hill, 2008. Andrade C, Canijo M, Klein D, Kaelin A: The genetic aspect of the familial amyloidotic polyneuropathy: Portuguese type of paramyloidosis. Humangenetik 7:163, 1969."
        },
        {
            "id": "Neurology_Adams_11898",
            "title": "Neurology_Adams",
            "content": "Special types of myokymia arise in childhood or adult life, sometimes in association either with a polyneuropathy or rarely with an inherited type of episodic ataxia that is variably responsive to acetazolamide or remits spontaneously (see Chap. 5). An inherited form of continuous muscle fiber activity has been traced to a mutation of the peripheral nerve K channel (Gutmann and Gutmann). In addition to the association with polyneuropathy, a state of continuous muscular activity has also been described in association with lung cancer and thymoma in which cases an immune mechanism has been inferred as noted above in Morvan syndrome (see reviews by Thompson and by Newsom-Davis and Mills and the discussion of paraneoplastic syndromes in Chap. 30)."
        },
        {
            "id": "Neurology_Adams_10676",
            "title": "Neurology_Adams",
            "content": "The polyneuropathy, when present, evolves over months or longer and may be asymmetrical, particularly at the onset, but becomes bilateral, mainly sensory, and distal. The pattern in our patients has been very slowly progressive, and initially limited to the feet and legs with sensory ataxia and loss of knee and ankle jerks. The CSF protein is usually elevated and the globulin fraction increased. In a case recorded by Rowland and colleagues, the polyneuropathy was purely motor and simulated motor neuron disease. Treatment is discussed further on."
        },
        {
            "id": "Neurology_Adams_10802",
            "title": "Neurology_Adams",
            "content": "a variant of the recessively inherited form of sensory neuropathy in which there was an associated neurotrophic keratitis and a selective loss of small myelinated fibers in sural nerve biopsies. We continue to observe variant and unclassifiable cases of purely motor, sensory, or mixed types in which genetic testing does not reveal a mutation such as these every year."
        },
        {
            "id": "Neurology_Adams_10813",
            "title": "Neurology_Adams",
            "content": "Although the nerves may not be palpably enlarged, \u201chypertrophic\u201d changes with onion-bulb formation are invariable pathologic features. The metabolic defect has been discovered to be in the utilization of dietary phytol; a failure of oxidation of phytanic acid\u2014a branched-chain tetramethylated 16-carbon fatty acid\u2014that accumulates in the absence of activity of the enzyme phytanoyl-CoA-hydroxylase. The relation between the increased phytanic acid and the polyneuropathy is uncertain. Clinical diagnosis is confirmed by the finding of increased phytanic acid in the blood of a patient with a chronic, mainly sensory neuropathy; the normal level is less than 0.3 mg/dL but in patients with this disease, it constitutes 5 to 30 percent of the total fatty acids of the serum lipids. Urinary phytanic acid concentration is also raised. Genetic testing reveals the mutation, which is in PHYH in 90 percent of cases and in PEX7 in the others."
        },
        {
            "id": "Neurology_Adams_10767",
            "title": "Neurology_Adams",
            "content": "The most prevalent form of the disease is CMT1A, which displays an autosomal dominant pattern of inheritance with almost complete penetrance; it is due to duplication of PMP 22 on chromosome 17p. Less often, CMT1 is autosomal recessive and even less frequently, X-linked dominant or X-linked recessive (see Table 43-6). Two common mutations in chromosomes 1 or 17 cannot be easily distinguished from one another on clinical grounds, but they have distinctive EMG features. The condition of hereditary liability to pressure palsies (HNPP) also displays an aberration on chromosome 17, but in the form of a deletion rather than a duplication of the gene for PMP22. This disease is discussed further on under \u201cBrachial Plexus Neuropathies.\u201d The X-linked variant is the result of a mutation of the gene for connexin-32, another component of myelin. In a large proportion of CMT2 cases, the genetic basis cannot be established with current clinically available genetic testing. Undoubtedly, further"
        },
        {
            "id": "Neurology_Adams_10988",
            "title": "Neurology_Adams",
            "content": "Said G, Slama G, Selva J: Progressive centripetal degeneration of axons in small fiber type diabetic polyneuropathy: A clinical and pathological study. Brain 106:791, 1983. Samanta A, Burden AC: Painful diabetic neuropathy. Lancet 1:348, 1985. Sandroni P, Vernino S, Klein CM, et al: Idiopathic autonomic neuropathy. Comparison of cases seropositive and seronegative for ganglionic acetylcholine receptor antibody. Arch Neurol 61:44, 2004. Saporta, ASD, Sottile SL, Miller LJ, et al: Charcot-Marie-Tooth disease subtypes and genetic testing strategies. Ann Neurol 69:22, 2011. Schaumburg HH, Berger AR, Thomas PK: Disorders of Peripheral Nerves, 2nd ed. Philadelphia, Davis, 1992. Schaumburg HH, Kaplan J, Windebank A, et al: Sensory neuropathy from pyridoxine abuse. N Engl J Med 309:445, 1983. Shahani BT, Young RR, Adams RD: Neuropathic tremor: Evidence on the site of the lesion. Electroencephalogr Clin Neurophysiol 34:800, 1973."
        },
        {
            "id": "Neurology_Adams_10654",
            "title": "Neurology_Adams",
            "content": "In these common syndromes, reduced sensation, weakness, muscular atrophy, and loss of tendon reflexes progress over a period of months or years. Within this large category, two groups are distinguished. In the first and less chronic of the two, the neuropathy appears over months or a year or two. Comprising this group are acquired processes such as certain metabolic and immune-mediated polyneuropathies. Paraneoplastic neuropathies may also fall into this category, although they are more often subacute in onset, being almost fully developed in a matter of weeks. Leprous neuritis is the one infectious member of this group and also the one exception to the rule that all chronic neuropathies are more or less symmetrical in pattern. The polyneuropathies that make up the second group are far more chronic than the first, evolving insidiously over many years or decades; these are mainly the genetically determined diseases of the peripheral nervous system caused by specific genetic mutations."
        },
        {
            "id": "Neurology_Adams_8953",
            "title": "Neurology_Adams",
            "content": "6. Hereditary spastic paraplegia with polyneuropathy Our colleagues had observed several patients in whom a sensorimotor polyneuropathy was combined with unmistakable signs of corticospinal disease. The age of onset was in childhood or adolescence, and the disability progressed to the point where the patient was chairbound by early adult life. In 2 of the cases, a sural nerve biopsy revealed a typical hypertrophic polyneuropathy; in a third case there was only a depletion of large myelinated fibers. The syndrome resembles the myeloneuropathy of adrenoleukodystrophy. 7. Spastic paraparesis with distal muscle wasting (Troyer syndrome, SPG20 mutation) This disorder is transmitted as an autosomal recessive trait in the Amish population. Onset is in childhood with amyotrophy of the hands, followed by spasticity and contractures of the lower limbs. Cerebellar signs (mild), athetosis, and deafness may be added. The mutation is in SPG20."
        },
        {
            "id": "Neurology_Adams_10853",
            "title": "Neurology_Adams",
            "content": "Table 43-7 lists the laboratory tests that we have found useful in the investigation of this group of neuropathies, with electrophysiology being most valuable. Diagnosis of Late Chronic Polyneuropathy"
        },
        {
            "id": "First_Aid_Step1_589",
            "title": "First_Aid_Step1",
            "content": "Charcot-Marie-Tooth Also called hereditary motor and sensory neuropathy. Group of progressive hereditary nerve disease disorders related to the defective production of proteins involved in the structure and function of peripheral nerves or the myelin sheath. Typically autosomal dominant and associated with foot deformities (eg, pes cavus, hammer toe), lower extremity weakness (eg, foot drop), and sensory deficits. Most common type, CMT1A, is caused by PMP22 gene duplication. Progressive multifocal Demyelination of CNS B due to destruction of oligodendrocytes (2\u00b0 to reactivation of latent leukoencephalopathy JC virus infection). Seen in 2\u20134% of patients with AIDS. Rapidly progressive, usually fatal. Predominantly involves parietal and occipital areas; visual symptoms are common. \u008f risk associated with natalizumab. Other disorders Krabbe disease, metachromatic leukodystrophy, adrenoleukodystrophy. Most common subtype of Guillain-Barre\u0301 syndrome."
        },
        {
            "id": "InternalMed_Harrison_31052",
            "title": "InternalMed_Harrison",
            "content": "alert the clinician to the possibility of amyloid polyneuropathy. Rarely, a pandysautonomic syndrome can be the only manifestation of a peripheral neuropathy without other motor or sensory findings. The majority of neuropathies are predominantly sensory in nature. approaCh to NeuropathiC DisorDers: seveN key questioNs 1. What systems are involved? Motor, sensory, autonomic, or combinations 2. What is the distribution of weakness? 3. What is the nature of the sensory involvement? -Temperature loss or burning or stabbing pain (e.g., small fiber) -Vibratory or proprioceptive loss (e.g., large fiber) 4. Is there evidence of upper motor neuron involvement? 5. What is the temporal evolution? Acute (days to 4 weeks) Monophasic, progressive, or relapsing-remitting 6. Is there evidence for a hereditary neuropathy? Family history of neuropathy Lack of sensory symptoms despite sensory signs 7. Are there any associated medical conditions?"
        },
        {
            "id": "Neurology_Adams_10403",
            "title": "Neurology_Adams",
            "content": "In the analysis of a polyneuropathy, it is of further value to determine whether the process is predominantly motor with less sensory involvement or the converse, or purely sensory, motor, or mainly autonomic. The time course of the disease also informs diagnosis. An acute onset (i.e., rapid evolution) is nearly always an inflammatory, immunologic, toxic, or vascular polyneuropathy. The other extreme, a polyneuropathy evolving over many years, is indicative of a hereditary or, rarely, a metabolic disease. Most of the toxic, nutritional, and systemic diseases of nerve develop subacutely over several weeks and months. In addition to the patient\u2019s report of the progress of symptoms, signs such as muscle atrophy signify a process of relatively long duration, at least several months."
        },
        {
            "id": "Neurology_Adams_10371",
            "title": "Neurology_Adams",
            "content": "in Chap. 8) Most polyneuropathies cause impairment of both motor and sensory functions, but one is often affected more than the other. In the toxic and metabolic neuropathies, sensory loss usually exceeds weakness. These differences are emphasized in the descriptions of individual peripheral nerve diseases in later parts of the chapter."
        },
        {
            "id": "InternalMed_Harrison_31084",
            "title": "InternalMed_Harrison",
            "content": "CMTDI In dominant-intermediate CMTs (CMTDIs), the NCVs are faster than usually seen in CMT1 (e.g., >38 m/s) but slower than in CMT2. CMT3 CMT3 was originally described by Dejerine and Sottas as a hereditary demyelinating sensorimotor polyneuropathy presenting in infancy or early childhood. Affected children are severely weak. Motor NCVs are markedly slowed, typically 5\u201310 m/s or less. Most cases of CMT3 are caused by point mutations in the genes for PMP-22, MPZ, or ERG-2, which are also the genes responsible for CMT1. CMT4 CMT4 is extremely rare and is characterized by a severe, childhood-onset sensorimotor polyneuropathy that is usually inherited in an autosomal recessive fashion. Electrophysiologic and histologic evaluations can show demyelinating or axonal features. CMT4 is genetically heterogenic (Table 459-4)."
        },
        {
            "id": "Neurology_Adams_10543",
            "title": "Neurology_Adams",
            "content": "Approximately 15 percent of patients with diabetes have symptoms and signs of polyneuropathy, but nearly 50 percent of cross-sectional population samples have evidence of peripheral nerve damage as judged by nerve conduction abnormalities. The duration of diabetes is perhaps the most important factor. Fewer than 10 percent of patients have clinically evident polyneuropathy at the time of discovery of diabetes, but this figure rises to 50 percent after 25 years. The presence of diabetic retinopathy is associated with higher incidences of neuropathy. It is not surprising, therefore, that neuropathy is most common in diabetics older than 50 years; it is infrequent in those younger than age 30 years and is rare in childhood. Dyck and colleagues (1993) studied diabetics in Rochester, Minnesota, and found that 54 percent with type 1 (insulin-deficient) and 45 percent with type 2 (insulin-resistant) had polyneuropathy. The percentages were lower when patients were selected on the basis of"
        },
        {
            "id": "Neurology_Adams_10655",
            "title": "Neurology_Adams",
            "content": "Acquired Forms of Chronic Polyneuropathy The occurrence of a chronic sensorimotor polyneuropathy in association with an abnormality of serum immunoglobulins is recognized with increasing frequency, but its boundaries are still not well established as will be apparent in the following discussion. The excess blood protein, called a paraprotein or \u201cM-spike,\u201d is usually in the form of a monoclonal immunoglobulin. It may be an isolated abnormality or a by-product of a plasma cell malignancy, specifically multiple myeloma, plasmacytoma, or Waldenstr\u00f6m macroglobulinemia. Several lines of evidence suggest that a pathogenetically active antibody against components of myelin or axon is present in at least some of these cases. Special forms of neuropathy are also associated with amyloidosis. Both the acquired and genetic forms of amyloidosis are discussed further on."
        },
        {
            "id": "Pathology_Robbins_4925",
            "title": "Pathology_Robbins",
            "content": "Mononeuritis multiplex, in which the damage randomly affects individual nerves, resulting (for example) in a right radial nerve palsy and wrist drop and, at a separate point in time, a left foot drop. Mononeuritis multiplex is often caused by vasculitis. A simple mononeuropathy only involves a single nerve and is most commonly the result of traumatic injury, entrapment (e.g., carpal tunnel syndrome), or certain infections such as Lyme disease. Many different diseases may be associated with peripheral neuropathy ( Table 22.1 ). We next discuss selected entities that are prototypical for a specific type of polyneuropathy or that are particularly common. Table 22.1 Peripheral Neuropathies InheritedCharcot-Marie-Toothneuropathy,type1,typeII,andX-linkedHereditaryneuropathywithliabilitytopressurepalsy OthersParaneoplastic,someleukodystrophies http://ebooksmedicine.net"
        },
        {
            "id": "Neurology_Adams_10407",
            "title": "Neurology_Adams",
            "content": "Diseases of the peripheral nerves are considered in a more comprehensive fashion in the two-volume Peripheral Neuropathy, edited by Dyck and colleagues and in the text by Amato and Russell cited in the references. Also recommended are more concise monographs by Schaumburg and associates and by Asbury and Thomas, and the atlas on the pathology of peripheral nerve by King. A number of differences separate the polyneuropathies in this category: (1) acute inflammatory demyelinating or axonal polyneuropathy (GBS), (2) vasculitic polyneuropathies, (3) porphyria, (4) certain toxic polyneuropathies, and (5) acute sensory and autonomic polyneuropathies. Of these various acute polyneuropathic diseases, the Guillain-Barr\u00e9 demyelinative syndrome, because of its frequency and gravity, is most demanding of the physician\u2019s attention. Guillain-Barr\u00e9 Syndrome (Landry-Guillain-Barr\u00e9-Strohl Syndrome, Acute Inflammatory Demyelinating Polyneuropathy, AIDP)"
        },
        {
            "id": "Neurology_Adams_10329",
            "title": "Neurology_Adams",
            "content": "In this single chapter, an attempt is made to provide an overview of the very large and difficult subject of peripheral nerve disease. Because the structure and function of the peripheral nervous system are relatively simple, one might suppose that our knowledge of its diseases would be fairly complete. Such is not the case. For example, when a group of patients with chronic polyneuropathy were investigated intensively in a highly specialized center for the study of peripheral nerve diseases several decades ago, a suitable explanation for their condition could not be found in 24 percent (Dyck et al, 1981) and equally discouraging figures prevail in our clinics today despite genetic testing. Moreover, the physiologic basis of many neuropathic symptoms continues to be elusive and in several of the neuropathies the pathologic changes have not been fully determined. However, rapidly advancing techniques in the fields of immunology and genetics are now clarifying entire categories of"
        },
        {
            "id": "Neurology_Adams_11203",
            "title": "Neurology_Adams",
            "content": "Distal bilateral limb palsies presenting as foot-drop with steppage gait (with or without pes cavus), weakness of all lower leg muscles, and later wrist-drop and weakness of hands The principal cause of this syndrome is a familial polyneuropathy, mainly of the Charcot-Marie-Tooth type (see Chap. 43); the course is over decades. Also presenting in this way are paraproteinemic and inflammatory polyneuropathies, with or without motor conduction block and exceptionally, some forms of familial progressive muscular atrophy and distal types of progressive muscular dystrophy, and sarcoid myopathy. In myotonic dystrophy, there may be weakness of the leg muscles as well as the forearms, sternocleidomastoids, face, and eyes. With these exceptions, the generalization that girdle weakness without sensory changes is indicative of myopathy and that distal weakness is indicative of neuropathy is clinically useful."
        },
        {
            "id": "InternalMed_Harrison_31050",
            "title": "InternalMed_Harrison",
            "content": "Peripheral NeuropathyChapter 459Patient Complaint: ? Neuropathy History and examination compatible with neuropathy? Mononeuropathy Mononeuropathy multiplex Polyneuropathy Evaluation of other \u02dcdisorder or \u02dcreassurance and follow-up EDx Is the lesion axonal \u02dcor demyelinating? Is entrapment or \u02dccompression present? Is a contributing systemic disorder present? Axonal Demyelinating \u02dcwith focal \u02dcconduction block Axonal Demyelinating Consider \u02dcvasculitis or other multifocal \u02dcprocess Consider \u02dcmultifocal \u02dcform of \u02dcCIDP Subacute \u02dccourse (months) Chronic \u02dccourse (years) Uniform slowing, \u02dcchronic Nonuniform slowing, conduction block Decision on need \u02dcfor surgery (nerve repair, \u02dctransposition, or release \u02dcprocedure) Possible \u02dcnerve \u02dcbiopsy Test for paraprotein, \u02dcHIV, Lyme disease Review history for toxins; test for associated systemic disease or intoxication Test for paraprotein, if negative Review family history; examine family members; genetic testing If chronic or \u02dcsubacute: CIDP If"
        }
    ],
    "scores": [
        0.03424582922971319,
        0.03389201597434043,
        0.025782703534997113,
        0.024922209665684016,
        0.022355739984764,
        0.02233979397870172,
        0.019692051602163963,
        0.019049346879535557,
        0.018480667688639072,
        0.018442971273159952,
        0.01690340909090909,
        0.016680339075745145,
        0.016312244089288074,
        0.015948659295971536,
        0.015705838876570587,
        0.0152073732718894,
        0.01507230255839822,
        0.014837581474219702,
        0.014836942992282796,
        0.014453748006379585,
        0.01441389843451699,
        0.014387464387464386,
        0.014361300075585788,
        0.014230206388454358,
        0.014141414141414142,
        0.014134452102687045,
        0.014064350572443741,
        0.013952380952380952,
        0.013683634373289545,
        0.01352329262777024,
        0.013483552780417176,
        0.0134446198962328
    ]
}